Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well‐controlled type 2 diabetes patients*
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: Bone metabolism is a dynamic process that is influenced by food ingestion. Endogenous incretins have been shown to be important regulators of bone turnover. The aim of the present study was to assess whether a dipeptidylpeptidase (DPP)‐4 inhibitor affects markers of bone resorption and calcium homeostasis. Methods: The present study was a single‐center, double blind, randomized clinical trail. Fifty‐nine drug‐naïve patients with type 2 diabetes (T2D) were randomized to either 1 year treatment with the DPP‐4 inhibitor vildagliptin (100 mg, once daily; n = 29) or placebo (n = 30). Patients received a standardized breakfast after measurement of serum concentrations of cross‐linked C‐terminal telopeptide (s‐CTx), a bone resorption marker influenced by food intake, before and after 50 weeks treatment. Results: Vildagliptin did not change postprandial s‐CTx concentrations compared with pretreatment levels (between‐group ratio 1.15 ± 0.17; P = 0.320). Fasting serum alkaline phosphatase, calcium, and phosphate were also unaffected y 1 year treatment with vildagliptin. Conclusions: Treatment with vildagliptin for 1 year was not associated with changes in markers of bone resorption and calcium homeostasis in drug‐naïve patients with T2D and mild hyperglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Foley, J. E., Bunck, M. C., Möller-Goede, D. L., Poelma, M., Nijpels, G., Eekhoff, E. M., Schweizer, A., Heine, R. J., & Diamant, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2167-8 · Cited by 83
Self-citation
Cited by
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Mulvihill, E. E., & Drucker, D. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1035 · Cited by 609
NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis
Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6095 · Cited by 286
Mabilleau, G., Mieczkowska, A., & Chappard, D. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12102 · Cited by 178
Overbeek, J. A., Bakker, M., van der Heijden, A. A. W. A., van Herk‐Sukel, M. P. P., Herings, R. M. C., & Nijpels, G. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3004 · Cited by 71
“The full texts of the remaining studies were evaluated for the inclusion and exclusion criteria, which resulted in a final inclusion of 25 studies.(2,3,17-39) For 4 studies, the authors were contacted, because the publications did not contain sufficient information regarding risk or variables needed to calculate the r…”
BackgroundSelf-citationc-Fos induction by gut hormones and extracellular ATP in osteoblastic-like cell lines
Pacheco-Pantoja, E. L., Dillon, J. P., Wilson, P. J. M., Fraser, W. D., & Gallagher, J. A. (2016) · Purinergic Signalling · doi:10.1007/s11302-016-9526-3 · Cited by 21
Metadata
- Authors
- BUNCK, M. C., POELMA, M., EEKHOFF, E. M., SCHWEIZER, A., HEINE, R. J., NIJPELS, G., FOLEY, J. E., & DIAMANT, M.
- Venue
- Journal of Diabetes
- Publisher
- Wiley
- Published
- 2012-05-15
- Volume
- 4
- Issue
- 2
- Pages
- 181-185
- ISSN
- 1753-0393 (ISSN-L)
- 1753-0407
- OpenAlex
- W1502015718
- Cited by
- 61
- References
- 2
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well‐controlled type 2 diabetes patients*. https://app.cochat.ai/papers/10.1111/j.1753-0407.2011.00168.x
- The paper
- BUNCK, M. C., POELMA, M., EEKHOFF, E. M., SCHWEIZER, A., HEINE, R. J., NIJPELS, G., FOLEY, J. E., & DIAMANT, M. (2012). Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well‐controlled type 2 diabetes patients*. Journal of Diabetes. https://doi.org/10.1111/j.1753-0407.2011.00168.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.